Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

@article{Falkson1991ImprovedRW,
  title={Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.},
  author={Conrad Falkson and Geoffrey Falkson and H{\`e}ndr{\'e} C. Falkson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1991},
  volume={9 8},
  pages={1403-8}
}
Sixty-four patients with histologically confirmed metastatic malignant melanoma were entered on a prospectively controlled randomized trial. Patients received dacarbazine (DTIC) alone or DTIC plus interferon (IFN) alfa-2b. Patients were reasonably balanced with respect to age, sex, performance status (PS), site of metastases, and number of metastatic sites. Objective response (complete plus partial remission [CR + PR]) was documented in six patients on DTIC and in 16 patients on DTIC plus IFN… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Current Cancer Therapeutics

Current Medicine Group • 2001
View 20 Excerpts
Highly Influenced

Strategies for Immunointerventions in Dermatology

Burg. Dummer
Springer Berlin Heidelberg • 1997
View 10 Excerpts
Highly Influenced

Fotemustine and interferon α2b in metastatic malignant melanoma

Journal of Cancer Research and Clinical Oncology • 1998
View 4 Excerpts
Highly Influenced

Long term survival with the combination of interferon and chemotherapy in metastatic melanoma.

Journal of the Egyptian National Cancer Institute • 2015
View 2 Excerpts

Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG • 2013

Similar Papers

Loading similar papers…